All Press Releases for August 20, 2020

Seeking Participants For COVID-19 Investigational Vaccine Studies

Phase III clinical trials

    OAK BROOK, IL, August 20, 2020 /24-7PressRelease/ -- Affinity Health, a Clinical Research Institute is seeking participants for COVID-19 investigational vaccine studies in their Oak Brook and Chicago, IL locations.

The Phase III clinical trials will help determine the safety and efficacy of investigational vaccines intended to protect against SARS-Cov-2, the coronavirus that causes COVID-19.

Affinity Health will conduct studies at its sites located at The Loretto Hospital (645 S. Central Avenue, Chicago) and at 2425 W. 22nd Street, #209, Oak Brook, IL 60523.

To be eligible, participants must be 18 or older. Participants will receive study-related exams, and an investigational COVID-19 vaccine or placebo at no cost.

As part of these studies, Affinity Health is seeking people who meet the following criteria:

• People who may be in close, regular contact with infected persons; this may include, but is not limited to essential workers, healthcare workers, first responders, manufacturing/factory workers, teachers, transit workers, etc.

• People without underlying health conditions, such as high blood pressure, diabetes, obesity, asthma, etc.

• Healthy individuals aged 18 years and above with no known history of COVID-19 infection.

Eligible participants will receive compensation for participating and do not need health insurance to join. People interested in joining a study can sign up for more information, at or by calling Affinity Health at (630) 491-1900.

Affinity Health provides quality healthcare, medical treatment, and offers a variety of clinical trials that supports global advancements in medicine. They strive to support their patients by providing them with multiple treatment options, including clinical trials, from skilled and caring medical service providers.

# # #

Contact Information

Nasreen Ahmed
Affinity Health Corp
Oak Brook, IL
Voice: (630) 491-1900
E-Mail: Email Us Here
Website: Visit Our Website
Blog: Visit Our Blog
Follow Us: